Recombinant human CD137L for cancer immunotherapy: effects of different fusions and linkers on its activity-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Recombinant human CD137L for cancer immunotherapy: effects of different fusions and linkers on its activity

Published:2011-10-04 Issue:4 Volume:61 Page:489-495
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Wang Shuzhen,Lv Junfang,Wang Peng,Yin Xiaojin,Tan Aimin,Chen Yijun

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1007/s00262-011-1097-0.pdf

Reference25 articles.

1. Tamada K, Chen L (2006) Renewed interest in cancer immunotherapy with the tumor necrosis factor superfamily molecules. Cancer Immunol Immunother 55:355–362

2. Melero I, Hervas-Stubbs S, Glennie M et al (2007) Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 7:95–106

3. Alderson MR, Smith CA, Tough TW et al (1994) Molecular and biological characterization of human 4–1BB and its ligand. Eur J Immunol 24:2219–2227

4. Cheuk AT, Mufti GJ, Guinn BA (2004) Role of 4–1BB:4–1BB ligand in cancer immunotherapy. Cancer Gene Ther 11:215–226

5. Lynch DH (2008) The promise of 4–1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer. Immunol Rev 222:277–286

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bifunctional Fusion Proteins Derived from Tumstatin and 4-1BBL for Targeted Cancer Therapy;Molecular Pharmaceutics;2018-12-19

2. Regulation of Myelopoiesis by CD137L Signaling;International Reviews of Immunology;2014-06-18

3. CD137L-stimulated dendritic cells are more potent than conventional dendritic cells at eliciting cytotoxic T-cell responses;OncoImmunology;2013-11

4. CD137 ligand signaling enhances myelopoiesis during infections;European Journal of Immunology;2013-04-24

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3